180 related articles for article (PubMed ID: 22418060)
21. Motor, emotional and cognitive deficits in adult BACHD mice: a model for Huntington's disease.
Abada YS; Schreiber R; Ellenbroek B
Behav Brain Res; 2013 Feb; 238():243-51. PubMed ID: 23123142
[TBL] [Abstract][Full Text] [Related]
22. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
Hickey MA; Reynolds GP; Morton AJ
J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
[TBL] [Abstract][Full Text] [Related]
23. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
24. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice.
Pang TYC; Stam NC; Nithianantharajah J; Howard ML; Hannan AJ
Neuroscience; 2006 Aug; 141(2):569-584. PubMed ID: 16716524
[TBL] [Abstract][Full Text] [Related]
26. Assessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for huntington disease.
Abada YS; Nguyen HP; Schreiber R; Ellenbroek B
PLoS One; 2013; 8(7):e68584. PubMed ID: 23874679
[TBL] [Abstract][Full Text] [Related]
27. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease.
Kung VW; Hassam R; Morton AJ; Jones S
Neuroscience; 2007 Jun; 146(4):1571-80. PubMed ID: 17478055
[TBL] [Abstract][Full Text] [Related]
28. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
[TBL] [Abstract][Full Text] [Related]
29. Altered emotional and motivational processing in the transgenic rat model for Huntington's disease.
Faure A; Höhn S; Von Hörsten S; Delatour B; Raber K; Le Blanc P; Desvignes N; Doyère V; El Massioui N
Neurobiol Learn Mem; 2011 Jan; 95(1):92-101. PubMed ID: 21111837
[TBL] [Abstract][Full Text] [Related]
30. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
31. Repeated isolation in the neonatal rat produces alterations in behavior and ventral striatal dopamine release in the juvenile after amphetamine challenge.
Kehoe P; Shoemaker WJ; Triano L; Hoffman J; Arons C
Behav Neurosci; 1996 Dec; 110(6):1435-44. PubMed ID: 8986344
[TBL] [Abstract][Full Text] [Related]
32. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
Tariq M; Khan HA; Elfaki I; Al Deeb S; Al Moutaery K
Brain Res Bull; 2005 Sep; 67(1-2):161-8. PubMed ID: 16140176
[TBL] [Abstract][Full Text] [Related]
33. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
Brown TB; Bogush AI; Ehrlich ME
Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688
[TBL] [Abstract][Full Text] [Related]
34. Manganese-induced hyperactivity and dopaminergic dysfunction depend on age, sex and YAC128 genotype.
Wilcox JM; Consoli DC; Paffenroth KC; Spitznagel BD; Calipari ES; Bowman AB; Harrison FE
Pharmacol Biochem Behav; 2022 Feb; 213():173337. PubMed ID: 35063467
[TBL] [Abstract][Full Text] [Related]
35. BACHD rats expressing full-length mutant huntingtin exhibit differences in social behavior compared to wild-type littermates.
Manfré G; Novati A; Faccini I; Rossetti AC; Bosch K; Molteni R; Riva MA; Van der Harst JE; Nguyen HP; Homberg JR
PLoS One; 2018; 13(2):e0192289. PubMed ID: 29415038
[TBL] [Abstract][Full Text] [Related]
36. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
[TBL] [Abstract][Full Text] [Related]
37. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hebb AL; Robertson HA; Denovan-Wright EM
Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
[TBL] [Abstract][Full Text] [Related]
38. Changes in striatal activity and functional connectivity in a mouse model of Huntington's disease.
Cabanas M; Bassil F; Mons N; Garret M; Cho YH
PLoS One; 2017; 12(9):e0184580. PubMed ID: 28934250
[TBL] [Abstract][Full Text] [Related]
39. Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test.
Borlongan CV; Randall TS; Cahill DW; Sanberg PR
Brain Res; 1995 Apr; 676(1):231-4. PubMed ID: 7796175
[TBL] [Abstract][Full Text] [Related]
40. Antagonistic effects of stimulation of the paramedian reticular nucleus in the rat medulla oblongata and of amphetamine on locomotor activity and striatal release of dopamine-like material.
Lin MT; Chuang SF; Li YC; Young MS; Chai CY
Naunyn Schmiedebergs Arch Pharmacol; 1993 Sep; 348(3):258-63. PubMed ID: 8232603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
